Stock Track | Cullinan Therapeutics Soars on Better-Than-Expected Q3 Earnings

Stock Track

Nov 09, 2024

Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.

The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.

Analysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a "buy" or "strong buy." The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126416601"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126416601\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126416601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126416601","market":"hk","top_or_hot":-1,"title":"Stock Track | Cullinan Therapeutics Soars on Better-Than-Expected Q3 Earnings","media":"Stock Track","content":"<p>Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.</p>\n\n<p>The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.</p>\n\n<p>Analysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a \"buy\" or \"strong buy.\" The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cullinan Therapeutics Soars on Better-Than-Expected Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cullinan Therapeutics Soars on Better-Than-Expected Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-09 00:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.</p>\n\n<p>The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.</p>\n\n<p>Analysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a \"buy\" or \"strong buy.\" The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"","article_id":"1126416601","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126416601","pubTimestamp":1731084265,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cullinan Therapeutics Inc.  surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.Analysts","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics"},"translate_title":"Cullinan Therapeutics第三季度盈利好于预期，股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1},"content_text":"Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.\nThe company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.\nAnalysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a \"buy\" or \"strong buy.\" The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}